EBV EA IgA (антитела IgA к раннему антигену вируса Эпштейна-Барр)

EBV Early Antigen (EA) IgG antibody testing—also termed anti‑EA IgG or EBV EA‑IgG—supports evaluation for Epstein–Barr virus infection across the clinical spectrum. The assay helps substantiate recent or acute infectious mononucleosis, differentiates mono‑like presentations during diagnostic workups, detects EBV reactivation, and contributes adjunctive evidence in the assessment of EBV‑associated malignancies, including Burkitt lymphoma and nasopharyngeal carcinoma.

Epstein–Barr virus (EBV), human herpesvirus 4, exhibits tropism for B lymphocytes and is a well‑recognized cause of infectious mononucleosis. EBV is also linked to several neoplastic disorders, including nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin disease, oral hairy leukoplakia, and B‑cell lymphomas. The virus is ubiquitous worldwide; in some regions up to 95% of individuals are infected by age 40 and harbor antibodies. Transmission occurs primarily through saliva. After entry via the oropharyngeal epithelium and salivary glands, EBV reaches the bloodstream and infects B cells, prompting their proliferation and enlargement of tonsils, lymph nodes, and spleen. In immunocompetent hosts, cellular immunity reduces circulating infected B cells and symptoms abate, but EBV establishes latency with the potential for asymptomatic reactivation. Reactivation is more likely with cellular immune impairment, including HIV infection, immunosuppressive therapy, pregnancy, and advanced age, and may contribute to oncogenesis. Primary infection is often silent or presents with mild pharyngitis or tonsillitis; classic infectious mononucleosis develops in approximately 35–50% of infected persons. The incubation period is 4–6 weeks. A prodrome of myalgias, fatigue, and malaise is followed by fever, sore throat, generalized lymphadenopathy, splenomegaly, and occasionally hepatomegaly; a rash on the trunk and extremities can occur. Symptoms typically persist for 2–4 weeks. Laboratory findings during the symptomatic phase commonly include atypical mononuclear cells exceeding 10% of lymphocytes and abnormalities in liver function tests. The principal EBV antigens for serologic evaluation are the viral capsid antigen (VCA), the early antigen (EA), and the EBV nuclear antigen (EBNA). Anti‑EA IgG appears in the acute phase of infection in approximately 70–85% of patients with infectious mononucleosis and usually declines to undetectable levels within 3–6 months; however, about 20% of individuals maintain detectable antibodies for years after recovery. EA comprises D (diffuse) and R (restricted) components defined by immunofluorescence patterns; moderate to high anti‑EA titers are observed in Burkitt lymphoma (predominantly R component) and nasopharyngeal carcinoma (predominantly D component. Demonstrating elevated titers to EA, EBNA, and VCA IgM together supports a diagnosis of primary EBV infection with approximately 95% accuracy. Rising anti‑EA alongside anti‑EBNA and anti‑VCA IgG suggests reactivation, particularly in settings of immunodeficiency, HIV infection, immunosuppressive therapy, pregnancy, or older age. An isolated increase in anti‑EA is not sufficient to diagnose chronic EBV infection and should be interpreted in conjunction with other EBV serologies, EBV PCR results, and clinical findings.